Citations

Institution: Mayo Clinic Clear

Showing 10 of 108094 citations.

Unravelling the myriad physiologic roles of transthyretin: critical considerations for treating transthyretin amyloidosis
Gertz, Morie A. , Aras, Mandar A. , Bart, N. , Brannagan, Thomas H., Griffin, Jan M. , Kontorovich, Amy , Rosen, Andrew M. , Kontorovich, Amy R , Gertz, Morie A , Brannagan, Thomas H.

Annals of Medicine | July 28, 2025 | Volume: 57 | Issue: 1 | Pages: No page available

10.1080/07853890.2025.2536755 | PMID 40717228 Get It

Disparities During Family-Centered Rounds for Families Using Languages Other Than English
Pelpola, Judith S., Rojas, Christina R. , Blakeney, Erin Abu‐Rish , Farkas, Jonathan S. , Everhart, Jennifer L., Fan, Angela L. , Johnson, Tyler , Kajiwara, Yuko, Knoebel, Erin, Lewis, Kheyandra D. , Mallick, Nandini, Markle, Peggy, Romano, Eileen M., Shaughnessy, Erin E. , Calaman, Sharon, Landrigan, Christopher P. , Khan, Alisa , Johnson, Tyler , García, Sonia , Graham, Dionne A. , Johnson, Tyler M., Romano, Eileen M., Baird, Jennifer D. , Spector, Nancy Dollase

Pediatrics | July 28, 2025 | Volume: 156 | Issue: 2 | Pages: No page available

10.1542/peds.2024-070285 | PMID 40716767 Get It

BACKGROUND/OBJECTIVE Patient- and family-centered rounds (PFCR) have become a pediatric standard of care. However, rounds experiences of families using languages other than English (LOE)—particularly languages other than English or Spanish (LOES; eg, Arabic)—receive less focus. We aimed to identify differences in PFCR communication and engagement by language. METHODS We analyzed postintervention data from a 21-center structured PFCR study, assessing communication practices, quality, and family and nurse engagement during PFCR. Logistic regression adjusted by site compared PFCR between families using (1) LOE vs English, (2) Spanish vs English, and (3) LOES vs English. RESULTS Among 3051 PFCR encounters, 348 (11.4%) involved LOE (Spanish = 260; LOES = 85). Interpretation was not used in 7.2%, 5.8%, and 9.4% of encounters using LOE, Spanish, and LOES, respectively. PFCR in the following groups had lower adjusted odds (adjusted odds ratio [95% CI]) for the following domains: (1) LOE vs English: including providing verbal patient summaries (0.66 [0.46–0.95]), explaining diagnoses and differentials (0.62 [0.44–0.88]), family engagement (0.34 [0.20–0.57]), nursing inclusion (0.75 [0.60–0.93]), and nursing engagement (0.69 [0.52–0.90]). (2) Spanish vs English: diagnoses/differentials being explained (0.56 [0.37–0.85]), family engagement (0.35 [0.18–0.67]), nursing inclusion (0.77 [0.59–1.00]), and nursing engagement (0.68 [0.52–0.89]). (3) LOES vs English: families sharing concerns (0.66 [0.47–0.93]), family engagement (0.30 [0.16–0.54]), and nursing inclusion (0.74 [0.55–0.99]). CONCLUSION Even after implementing a PFCR intervention, families using LOE—especially LOES—experienced significant disparities in communication and engagement. Future approaches to improving PFCR should emphasize language access and promote nurse and family engagement for families using LOE, particularly LOES.
Effort thrombosis: Paget–Schroetter syndrome in a 19-year-old female
Adetimehin, Omobolanle, Oke, Ibiyemi

International Journal of Case Reports and Images | July 27, 2025 | Volume: 16 | Issue: 2 | Pages: 10-13

10.5348/101514z01oa2025cr Get It

Paget–Schroetter syndrome (PSS) is a form of effort thrombosis seen in young athletes and individuals with occupations involving repetitive upper limb movement. Arm swelling, distended veins, skin discoloration, and pain are characteristics of it. Diagnosis can be made with non-invasive investigations, such as Doppler ultrasound; however, a computed tomography venogram, magnetic resonance venogram, or traditional venogram may be required. Treatment involves anticoagulation, thrombolysis, and surgical decompression with removal of the first rib, and this is usually met with good outcomes. We present a young female diagnosed with PSS and requiring a staged multidisciplinary approach to treatment.
Breast Cancer Method of Detection: Frequently Asked Questions
Bahl, Manisha , Aminololama‐Shakeri, Shadi , Chen, L, Chikarmane, Sona A. , Dontchos, Brian N. , Lampen-Sachar, Katharine , Langman, Eun L. , Rosen, Eric L. , Rossi, Joanna , Ghate, Sujata V. , Dontchos, Brian N , Ojeda-Fournier, Haydee , Rossi, Joanna , Sharpe, Richard E. , Destounis, Stamatia V. , Eby, Peter R.

Journal of Breast Imaging | July 26, 2025 | Volume: 7 | Issue: 6 | Pages: 718-728

10.1093/jbi/wbaf048 | PMID 41183368 Get It

Abstract The initial method of detection (MOD) refers to the first imaging examination, physical symptom, or clinical sign that prompts further investigation and ultimately leads to a new breast cancer diagnosis. The MOD is assigned at the patient level and falls into 1 of 3 categories: screening in asymptomatic patients, detection by patients or health care providers, or neither of the above. The MOD should be assigned prospectively by the radiologist when interpreting an examination with a final BI-RADS category of 4 or 5, before image-guided biopsy and breast cancer diagnosis. The MOD is not assigned to examinations classified as BI-RADS category 0, 1, 2, 3, or 6, nor is it assigned in the setting of an active breast cancer diagnosis. This Clinical Practice article addresses frequently asked questions and challenging clinical scenarios compiled by the American College of Radiology’s Screening and Emerging Technology Committee to guide consistent MOD assignment. For example, if a patient presents with a lump but is ultimately found to have a suspicious finding requiring biopsy in the contralateral breast, the MOD should reflect the reason for presentation, the patient-detected symptom (Pat), even if the cancer itself is asymptomatic. By increasing awareness of MOD and standardizing MOD reporting practices, radiologists can contribute to improved data collection. While MOD is not currently tracked in U.S. cancer registries, its systematic collection may offer valuable insights into screening effectiveness, technology performance, and disparities in cancer detection. Standardized MOD reporting has the potential to strengthen early detection efforts and improve outcomes across diverse clinical settings.
A Clinically Applicable Model Using Blood Counts to Support the Diagnosis of Prefibrotic Myelofibrosis Versus Essential Thrombocythemia
Barbui, Tiziano , Thiele, Jürgen, Kvasnicka, H. M. , Gisslinger, Heinz , Vannucchi, Alessandro M. , Orazi, Attilio , Tefferi, Ayalew , Gisslinger, Heinz , Vannucchi, Alessandro M , Orazi, Attilio , Tefferi, Ayalew , Ghirardi, Arianna , Gianelli, Umberto , Arber, Daniel A.

American Journal of Hematology | July 26, 2025 | Volume: 100 | Issue: 10 | Pages: 1772-1778

10.1002/ajh.70017 | PMID 40716107 Get It

ABSTRACT This study aimed to distinguish between essential thrombocythemia (ET) and prefibrotic primary myelofibrosis (pre‐PMF) using routine blood tests, with a focus on white blood cell (WBC) and platelet (PLT) levels. We evaluated the predicted probability of a pre‐PMF diagnosis based on the interaction between WBC and PLT levels using data from a logistic regression model involving 891 patients with ET and 180 patients with pre‐PMF. Patients were divided into four groups based on whether their WBC and PLT values were below or above the respective thresholds of 8.85 × 10 9 /L and 793 × 10 9 /L. The results showed that patients with low levels of both WBCs and PLTs had the lowest predicted probability of pre‐PMF (6%), indicating a profile more typical of ET. When either WBC or PLT levels were elevated, the probability increased to approximately 18%–19%, indicating a potential shift toward pre‐PMF features. Notably, patients with elevated levels of both WBCs and PLTs had the highest probability of a pre‐PMF diagnosis (26%), which was more than four times higher than that of the low–low group. The association between combined WBC/PLT levels and a pre‐PMF diagnosis remained significant ( p < 0.001), even when adjusting for serum lactate dehydrogenase (LDH) and splenomegaly. These findings suggest that elevated WBC and PLT levels together can serve as a practical and accessible diagnostic tool for supporting the differential diagnosis of ET or pre‐PMF in cases of uncertainty, and for deferring bone marrow biopsy in cases of early disease presenting with isolated thrombocytosis.
MAGIS syndrome: Phenotypes, pathogenesis, and treatment
Lamborn, Ian T. , Jing, Huie , Chattopadhyay, Eesha, Ham, Hyoungjun , Zhang, Yu , Su, Helen C. , Zhang, Yu , Su, Helen C , Chattopadhyay, Eesha

Journal of Human Immunity | July 26, 2025 | Volume: 1 | Issue: 4 | Pages: No page available

10.70962/jhi.20250065 | PMID 40926810 Get It

Inborn errors of immunity (IEI) presenting with immunodeficiency and autoimmunity can illuminate pathways essential for immunocompetence and self-tolerance. We recently characterized a new IEI named MAGIS (“Midline malformations of the brain, Anterior pituitary gland dysfunction, Growth retardation, Immunodysregulation/Immunodeficiency, and Skeletal defects”) caused by heterozygous germline-activating mutations in GNAI2 (encoding the heterotrimeric G protein, Gαi2). This disorder demonstrates the central role of Gαi2 regulation of chemotaxis in humans and a novel pathway by which G proteins regulate T cell activation. Here, we review the clinical features, current genetic and biochemical understanding, and future therapeutic considerations for this new syndromic immune dysregulation disorder.
Anti‐Tumor Activity of Paclitaxel‐Containing Regimens in Recurrent/Refractory Wilms Tumor
Groisser, Alissa , Frantz, Amy, Geller, James I. , Ortiz, Michael V. , Walterhouse, David , Ranalli, Mark , Woods‐Swafford, Wendy, Schoettler, Peter , Garrington, Timothy , Mullen, Elizabeth A. , Ash, Shifra , Bardhan, Pooja, Dome, Jeffrey S. , Dome, Jeffrey S , Groisser, Alissa R. , Balis, Frank M.

Pediatric Blood & Cancer | July 26, 2025 | Volume: 72 | Issue: 10 | Pages: No page available

10.1002/pbc.31915 | PMID 40714994 Get It

ABSTRACTBackgroundThe Pediatric Oncology Group P9262 Phase 2 study of single‐agent paclitaxel demonstrated one complete response (CR), one partial response (PR), and four with stable disease (SD) among 15 patients with recurrent Wilms tumor (WT). Based on this activity, paclitaxel‐containing regimens have been used as salvage therapy for treatment‐refractory WT. We conducted a multi‐institutional retrospective study to further characterize the clinical activity of paclitaxel‐containing regimens in recurrent WT.MethodsTwelve institutions submitted anonymized data from patients with relapsed WT treated with paclitaxel. Response after one or two cycles of a paclitaxel‐containing regimen was reported according to Response Evaluation Criteria in Solid Tumors.ResultsTwenty‐eight patients with a median age at diagnosis of 5.5 years (range: 3 months to 31.9 years) were reported. Twenty had non‐anaplastic WT; eight had diffuse anaplasia (DA). Stage at diagnosis was I (n = 1), II (n = 1), III (n = 11), IV (n = 14), and V (n = 1). Patients received a mean of 8.5 anticancer drugs (range: 6–12) before paclitaxel, including eight who received high‐dose therapy/stem cell transplant. Paclitaxel (n = 13) or nab‐paclitaxel (n = 15) were predominantly administered in combination with other agents, most commonly doxorubicin and/or gemcitabine. Eleven of 26 patients with measurable disease had a partial response (7 = non‐anaplastic; 4 = DA), four had stable disease, and 11 had progressive disease. Two patients without measurable disease maintained a complete response for 12 and 16 months. The mean duration without progression was 7.6 months (range: 1–35 months).ConclusionsPaclitaxel‐containing regimens appear to be active against heavily pretreated WT with either non‐anaplastic or DA histology. Prospective studies are warranted to formally evaluate the efficacy of paclitaxel‐based therapies.
Adaptive‐driven CT simulation‐free multi‐fraction SBRT radiotherapy: Initial clinical experience
Malkov, Victor , Kemp, Bradley J. , Ferrero, Andrea , Buchholtz, Lori M., Kavanaugh, James , Kavanaugh, J A , Park, S. S.

Journal of Applied Clinical Medical Physics | July 26, 2025 | Volume: 26 | Issue: 8 | Pages: No page available

10.1002/acm2.70147 | PMID 40714933 Get It

AbstractIntroductionUsing diagnostic CT for radiotherapy (RT) planning can bypass traditional CT simulation but introduces challenges in patient positioning and Hounsfield unit (HU) fidelity, affecting dose accuracy. Here a Varian Ethos adaptive‐driven CT direct‐to‐treatment (DtT) multi‐fraction stereotactic body radiation therapy (SBRT) workflow is presented.MethodsThis study employed institutional diagnostic PET‐CT images to generate an initial reference Ethos treatment plan. HU and dosimetric accuracy were validated for PET‐CT, Ethos CBCT images (with and without Hypersight (HS), and the gold‐standard helical CT simulators). Following the SBRT reference plan creation on the low dose diagnostic PET‐CT, the first fraction was delivered with a newly generated adaptive plan calculated on the HS CBCT (Ethos) images. For multi‐fraction treatments, the first day CBCT images and adaptive plan become the reference for subsequent IGRT treatments. This study includes workflow validation and initial three patient experience.ResultsThe DtT adaptive SBRT workflow was successfully implemented, with initial end‐to‐end testing demonstrating feasibility. In‐house solutions were introduced to facilitate the adaptive to IGRT plan conversion. The Ethos system, especially with HS, maintained HU fidelity and dose calculation accuracy comparable to helical CTs. On‐table adaptive sessions were within 37–51 min, aligning with single‐fraction palliative studies. Subsequent non‐adaptive IGRT fractions were efficiently completed within 7–27 min.ConclusionsThis study demonstrates the feasibility of DtT adaptive‐driven multifraction SBRT using diagnostic PET‐CT. This approach reduces the need for on‐site patient presence prior to treatment, expands planning lead times, and improves overall efficiency in radiotherapy for well selected patients.
Venous Thromboembolism Outcomes Among Cancer and Non-cancer Patients Managed with Patient-centric Guideline-driven Protocol
Cassianni, Claire , Vlazny, Danielle T. , Hodge, David O. , Cassianni, Claire E , McBane, Robert D. , Casanegra, Ana I. , Houghton, Damon E. , Wysokiński, Waldemar E.

Thrombosis and Haemostasis | July 25, 2025 | Volume: 126 | Issue: 05 | Pages: 518-525

10.1055/a-2653-6161 | PMID 40719144 Get It

Abstract Patients with cancer and venous thromboembolism (VTE) have higher complication rates of anticoagulation. However, studies supporting this data are relatively old reflecting the era of vitamin K inhibitors. To assess VTE recurrence, major bleeding, and clinically relevant non-major bleeding (CRNMB) in patients (March 1, 2013 to April 30, 2023) with cancer-associated VTE and patients without cancer, the prospective Mayo Clinic Thrombophilia Clinic Registry was analyzed. Over the study period, 4,711 patients with acute VTE were enrolled including 2,064 patients with cancer (mean age 62.5 ± 12.4, 46% female) and 2,647 patients without cancer (mean age 59.4 ± 16.0, 45% female). The most common cancers were gastrointestinal (n = 423, 21%), pancreatic (n = 287, 14%), and genitourinary (n = 198, 10%). Direct oral anticoagulants were used in 1,339 (65%) cancer and in 1,952 (74%) non-cancer patients. Among cancer patients, 12-month Kaplan–Meier probability of VTE recurrence was 2.4-fold greater (7.1% vs. 2.9%, p < 0.001) compared with the non-cancer group, including higher recurrent leg deep vein thrombosis (3.0% vs. 1.4%; p = 0.002) and pulmonary embolism (3.5% vs. 1.0%, p < 0.001). Patients with cancer also had 2.1-fold greater risk of major bleeding (6.3% vs. 3.0%; p < 0.001) including bleeding from the gastrointestinal tract (3.0 vs. 1.4, p = 0.01) compared with patients without cancer. Clinically relevant non-major bleeding events were similar between the groups. In this large prospective registry of VTE management, patients with cancer had significantly higher rates of VTE recurrence and major bleeding compared with patients without cancer, yet the rate of complications are substantially smaller relative to historic values of a prior vitamin K antagonist era.
Midlife Retinal Microvascular Signs and Late-Life Neuroimaging Features of Cerebral Small Vessel Disease in the ARIC Study
Jiang, Kening , Power, Melinda C. , Bandeen‐Roche, Karen , Griswold, Michael , Albert, Marilyn , Knopman, David S. , Mosley, Thomas H. , Walker, Keenan A. , Sharrett, A. Richey, Egle, Marco , Mosley, Thomas H. , Knopman, David S. , Griswold, Michael , Albert, Marilyn S. , Gottesman, Rebecca F , Egle, Marco , Deal, Jennifer A , Walker, Keenan A , Gottesman, Rebecca F. , Deal, Jennifer A.

Neurology | July 25, 2025 | Volume: 105 | Issue: 4 | Pages: No page available

10.1212/wnl.0000000000213919 | PMID 40712116 Get It